Omnicell (NASDAQ:OMCL) EVP Corey Manley Sells 7,405 Shares

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 7,405 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares of the company’s stock, valued at $3,355,112.73. The trade was a 7.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Omnicell Stock Performance

Shares of OMCL opened at $35.09 on Wednesday. The firm’s 50 day moving average is $43.27 and its 200-day moving average is $38.53. The stock has a market capitalization of $1.59 billion, a P/E ratio of 877.47, a P/E/G ratio of 1.23 and a beta of 0.79. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). The business had revenue of $313.98 million for the quarter, compared to analyst estimates of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP grew its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after purchasing an additional 1,265,818 shares in the last quarter. Millennium Management LLC acquired a new position in Omnicell during the third quarter valued at approximately $25,625,000. Boston Partners acquired a new position in Omnicell in the 4th quarter valued at $20,805,000. Two Sigma Investments LP increased its stake in shares of Omnicell by 93.8% in the third quarter. Two Sigma Investments LP now owns 559,969 shares of the company’s stock worth $17,051,000 after purchasing an additional 271,008 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 9.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after purchasing an additional 197,462 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research reports. Wall Street Zen lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research report on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Wednesday, February 4th. Finally, Weiss Ratings downgraded Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average price target of $55.29.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.